Baird analyst David Rescott initiated coverage of Procept BioRobotics (PRCT) with a Neutral rating and $30 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics Balances Rapid Growth With Profit Push
- Procept BioRobotics price target lowered to $30 from $62 at UBS
- Procept BioRobotics price target lowered to $30 from $47 at Truist
- Procept BioRobotics price target lowered to $34 from $50 at TD Cowen
- Procept BioRobotics price target lowered to $28 from $50 at Piper Sandler